MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Summary

Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM) patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT) followed by maintenance therapy with MEDI-551.

Timeline

Start

2017-09-27

Primary completion

2018-04-15

Completion

2018-04-15

Outcome

Outcome not reported

Stopped: “MEDI-551 removed from oncology by pharmaceutical company due to change in research target.”

Drugs

Indications